WinstonWınston
TAKE Solutions Limited logo

TAKE Solutions Limited

TAKE.NS
18
Biotechnology · Healthcare
Price
₹20.79
+0.02 (+0.10%)
Market Cap
₹3.04B
Exchange
National Stock Exchange of India
Winston Score
18
Winston is worried
Weak fundamentals across most pillars.
Data as of Jul 26, 2026 · filings through Mar 31, 2026

TAKE Solutions Limited, operating across the United States, Asia Pacific, and Europe, specializes in providing expert services and cutting-edge solutions for the life sciences and supply chain management sectors. For the life sciences industry, the company delivers technology-driven and proprietary solutions, alongside consulting and practical services covering clinical trials, regulatory compliance, and patient safety. Its specific offerings in this area include clinical research, development of generic drugs, data analytics, regulatory affairs management, and pharmacovigilance. Beyond this, TAKE Solutions also offers IT infrastructure and support, comprehensive supply chain management, engineering, design, and sourcing services. The company caters to a diverse client base, encompassing both major and smaller innovative biopharmaceutical and medical device firms, as well as generic drug producers. Established in 2000, its main office is located in Chennai, India. TAKE Solutions Limited functions as a subsidiary of TAKE Solutions Pte. Limited.

Winston Score History

Share count broadly stable

+0.3% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 146.2M (2022) → 146.6M (2026)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
-0.1%
Thin — -0.1% gross margin
Operating Margin
-1.5%
Losing money on operations — -1.5%
ROCE
-2.7%
Weak — -2.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
N/A
Data not available
EPS YoY
-71.3%
Earnings shrinking (-71.3% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
-29%
Weak — only -29% of profit becomes cash
FCF Margin
-5.8%
Burning cash (-5.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
28.3x
Growth-priced — P/E 28.3

P/E above the market average. People are paying up for expected growth.

P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial